Actively Recruiting Studies and Clinical Trials

Our Center supports a wide variety of Alzheimer’s disease-related research. If you are interested in participating in one of our studies, please call 617-414-1077 or email joinADC@bu.edu for more information.

Although there may not be a study for you right now, there may be a study for you in the future.  Please still give us a call so we can keep you up to date on future studies.

Clinical Trials

DAYBREAK

This clinical research study will examine an oral investigational drug called LY3314814.  The study is designed to find out whether this study drug can slow down the decline in memory and mental functioning.

Eligibility: Are between 55 and 85 years old and have experienced a gradual loss of memory over the last 6 months (the study team will assess whether this is due to Alzheimer’s disease) OR have been diagnosed with mild Alzheimer’s disease and have a close friend, relative or partner who would be willing to be your study partner throughout the study.

Read More

Amaranth

The purpose of the Amaranth study is to assess the effects of AZD3293 in patients with a diagnosis of MCI or Mild Alzheimer’s disease. This study has four essential arms, where a participants may be on placebo or active medication.

Eligibility: Are between the ages of 55-85 with MCI or Mild AD

Axovant DLB Study

This clinical trial is examining the effects of RVT -101-2001 in patients who have been diagnosed with dementia with Lewy bodies (DLB).

Eligibility: Are between the ages 50-85 and diagnosed with a diagnosis of Dementia with Lewy Bodies

Biogen/Emerge/Engage

This study examines the effects of aducanumab in patients with MCI. This medication works to remove existing plaques and prevent future plaque formation.

Eligibility: Are between the ages 50-85 with a diagnosis of MCI

TTP-STEADFAST

The vTv Pharmaceuticals trial, TTP488-301, is an 18-month study analyzing the efficacy and safety of a disease modifying compound, Azeliragon or TTP488.

Eligibility: Are 50 years or older and diagnosed with mild Alzheimer’s Disease

REVEAL-SCAN Study

REVEAL-SCAN is an NIH-funded, multisite clinical trial that will explore the impact of learning amyloid imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer’s disease (AD).

Eligibility: Are between the ages of 65-80 and are a healthy adult

Alzheimer’s Disease Neuroimaging Initiative 3

ADNI 3 aims to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer’s disease (AD).

Eligibility: Are between the ages of 55-90 and are Healthy Aduls or individuals with MCI or AD.

EARLY

This study examines the effects of a BACE inhibitor on preventing cognitive decline in participants with no cognitive impairments. The primary objective of this study is to determine whether treatment slows cognitive decline compared with a placebo treatment, as measured by a composite cognitive measurement, the Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive subjects who are asymptomatic at risk for developing Alzheimer’s Dementia.

Eligibility: Are between the ages of 50-85 years old and is a healthy adult.

Detection and Diagnosis

Health Outreach Program for the Elderly (HOPE)

The HOPE study is the BU ADC main registry of participants. People who join HOPE attend a yearly visit in which their memory and thinking abilities are evaluated. They also participate in other BU ADC affiliated studies.

Eligibility: Healthy adults, MCI, AD

Read More

Caregiving

Advanced Care Planning

The purpose of this study is to better understand caregivers’ knowledge, thoughts, and actions regarding health care planning for individuals who have memory problems and dementia.

Eligibility: Caregiver or informant for a person who has memory problems or dementia

Exercise Studies

Aerobic Exercise, Neurotrophins, and fMRI

This study is investigating the effects of exercise and cardiovascular fitness on cognitive processes, brain function, and levels of certain proteins in the blood.

Eligibility: Are between the ages of 18-35 or 55-85 and are a healthy, sedentary adult

Feasibility of using physical activity monitoring for enhancing cognition in healthy seniors

The goal of this study is to examine whether digital self-monitoring of physical activity, with the goal to reach at least 150 minutes of moderate-intensity physical activity per week over a 12-week period, can improve cognition and functional fitness comparable to an aerobic exercise program of the same duration in initially physically inactive healthy seniors.

Eligibility: Are between the ages of 55-85

Read More

Other Studies

The Light Study

This study is looking at detect changes in the brain associated with aging and cognitive impairment using near infrared spectroscopy (NIRS).

Eligibility: Are between ages 65-85 years old and are a healthy adult, or diagnosed with MCI or AD

Subclinical Paroxysmal EEG Abnormalities in Alzheimer’s Disease

The purpose of this research study is to find out if patients with early Alzheimer’s disease have periods of abnormal brain activity, such as seizures, that might explain some of their memory problems.

Eligibility: Are between the ages of 50-90 and are a healthy adult,or diagnosed with MCI or Lewey Body Dementia

Near Infrared Spectroscopy and Electroencephalography of Brain Function

This study is designed to research a new system designed to measure brain activity by taking a series of measurements while a variety of tasks are performed.

Eligibility: Are between 65 and 74 and who are healthy individuals or individuals diagnosed with MCI.

Metal Exposure and Alzheimer’s Disease

The primary aim of this project is to determine whether environmental metal exposure increases risk of Alzheimer’s Disease (AD). Draw less than two tablespoons of blood from the participants’ veins. This will take about 5 minutes. The blood will be tested for metal and dementia-related proteins and genes, including ApoE4 which has been shown to be a risk factor for Alzheimer’s disease.

Eligibility: Are between 50-100 years who are healthy older adults or individuals and who have probable AD.

False Memory

This study looks at participant responses to certain cognitive testing. Research suggests that patients with different types of brain problems perform differently on certain tests. The goal of this study is to better understand how different brain problems affect perception, thinking and memory, hopefully leading to better diagnostic evaluations.

Eligibility: Are between 65-90 years old who are healthy adults or diagnosed with MCI or AD.

Alzheimer’s Association National Chapter
Alzheimer’s Association MA/NH Chapter
National Institute on Aging’s Alzheimer’s Disease Education and Referral Center
Boston Medical Center Memory Disorder’s Clinic
AlzForum
Clinical Trials.gov
Alzheimers.net